Last reviewed · How we verify
monoclonal antibody HeFi-1
At a glance
| Generic name | monoclonal antibody HeFi-1 |
|---|---|
| Sponsor | Beth Israel Deaconess Medical Center |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Phase I Study of HeFi-1 to Treat Cancers With CD30 Protein (PHASE1)
- Monoclonal Antibody Therapy in Treating Patients With Refractory Anaplastic Large Cell Lymphoma or Hodgkin's Lymphoma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- monoclonal antibody HeFi-1 CI brief — competitive landscape report
- monoclonal antibody HeFi-1 updates RSS · CI watch RSS
- Beth Israel Deaconess Medical Center portfolio CI